Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28165171 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL4285086 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL28273729 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL10739048 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL10739485 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL24176160 | 0.91 | TDP1 (0.65) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL4035829 | 0.86 | TDP1 (0.59) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL28838938 | 0.86 | TDP1 (0.59) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL8397091 | 0.85 | HTT (0.62) | TDP1HTTNAMPTKMT2AMEN1 | |
| SCHEMBL10520613 | 0.84 | NAMPT (0.59) | TDP1HTTNAMPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TDP1 2211/4885HTT 4346/4885NAMPT 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.